Valomaciclovir: Phase IIb data

Data from a double-blind, North American Phase IIb trial (EPB348-0201) trial in 373 patients showed that the two highest doses (2 and 3 g) of once-daily valomaciclovir met the primary endpoint of non-inferiority to thrice-daily Valtrex valacyclovir in time to complete crusting of shingles rash. The lowest dose (1 g) of valomaciclovir missed the primary endpoint. The highest dose of valomaciclovir was superior to Valtrex in time to complete crusting of shingles rash (p<0.007). ...